-
公开(公告)号:US12121725B2
公开(公告)日:2024-10-22
申请号:US16941911
申请日:2020-07-29
IPC分类号: A61N1/05 , A61B5/00 , A61B5/145 , A61B5/15 , A61B5/20 , A61B18/14 , A61N1/36 , A61B5/157 , A61B10/00 , A61B18/00 , A61B18/02 , A61B18/18 , A61N1/32 , A61N1/40 , A61N7/02 , G01N33/68
CPC分类号: A61N1/3606 , A61B5/14546 , A61B5/15003 , A61B5/201 , A61B5/4848 , A61B18/1492 , A61N1/0551 , A61N1/3605 , A61N1/36121 , A61B5/1405 , A61B5/14503 , A61B5/15 , A61B5/150229 , A61B5/150992 , A61B5/157 , A61B5/20 , A61B5/4035 , A61B5/4836 , A61B5/6851 , A61B5/6852 , A61B5/6853 , A61B5/6858 , A61B10/0045 , A61B10/007 , A61B2018/00166 , A61B2018/00214 , A61B2018/0022 , A61B2018/00232 , A61B2018/00279 , A61B2018/00345 , A61B2018/00404 , A61B2018/00434 , A61B2018/00511 , A61B2018/00577 , A61B2018/00642 , A61B2018/00875 , A61B18/02 , A61B2018/0212 , A61B18/18 , A61N1/05 , A61N1/32 , A61N1/36007 , A61N1/36135 , A61N1/40 , A61N7/02 , G01N33/68 , G01N2800/347
摘要: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to biomarker sampling in the context of neuromodulation devices, systems, and methods. Some embodiments, for example, are directed to catheters, catheter systems, and methods for sampling biomarkers that change in response to neuromodulation. A system can include, for example, an elongated shaft and a neuromodulation and sampling assembly having a neuromodulation and a sampling element.
-
公开(公告)号:US12121379B2
公开(公告)日:2024-10-22
申请号:US17463009
申请日:2021-08-31
申请人: Medtronic, Inc.
CPC分类号: A61B6/12 , A61B6/032 , A61B90/39 , A61N1/05 , A61B2090/3966
摘要: Devices, systems, and techniques are disclosed for determining an orientation of an implanted medical lead. For example, a system may include processing circuitry configured to receive image data representing a lead implanted within a patient, identify, from the image data, at least one hypointensive portion, identify, from the image data, at least one hyperintensive portion, determine, based on the at least one hypointensive portion and the at least one hyperintensive portion, an orientation of the lead within the patient, and output the orientation of the lead.
-
公开(公告)号:US12121299B2
公开(公告)日:2024-10-22
申请号:US17313736
申请日:2021-05-06
CPC分类号: A61B18/203 , A61N5/0616 , A61N2005/005 , A61N2005/0632
摘要: In some embodiments, an apparatus comprises a stationary frame and a thermal ring. The thermal ring may be rotatably coupled to the stationary frame and disposed relative to the stationary frame such that the thermal ring and the stationary frame define an enclosure. The thermal ring may include a thermally-conductive substrate configured to be in thermal contact with a heat-generating component. Heat from the heat-generating component may be transferred to the stationary frame via the enclosure.
-
公开(公告)号:US20240349418A1
公开(公告)日:2024-10-17
申请号:US18319504
申请日:2023-05-18
发明人: Cheng-Ji LU , Zhen-Fan YOU
CPC分类号: H05H3/06 , A61N5/10 , A61N2005/007 , A61N2005/109 , H05H2242/10
摘要: A heat dissipation structure includes a housing. The housing has opposing upper and lower surfaces, and a fluid channel between the upper surface and the lower surface. The fluid channel is configured to allow a fluid to pass through, and the fluid channel includes an inlet buffer tank, an outlet buffer tank and a connecting structure. The inlet buffer tank has opposing first inner wall and second inner wall surfaces. The outlet buffer tank has opposing first inner wall and second inner wall surfaces, and the second inner wall surface is closer to the inlet buffer tank than the first inner wall surface. The connecting structure is disposed on the inlet buffer tank and the outlet buffer tank, in which the connecting structure has a first bevel surface and a second bevel surface connected to the upper surface of the housing.
-
公开(公告)号:US20240348995A1
公开(公告)日:2024-10-17
申请号:US18632896
申请日:2024-04-11
CPC分类号: H04R25/507 , A61N1/36036 , H04R25/407 , H04R25/552 , H04R1/1008 , H04R5/033 , H04R25/554 , H04R2225/43 , H04R2460/13
摘要: A hearing system performs nonlinear processing of signals received from a plurality of microphones using a neural network to enhance a target signal in a noisy environment. In various embodiments, the neural network can be trained to improve a signal-to-noise ratio without causing substantial distortion of the target signal. An example of the target sound includes speech, and the neural network is used to improve speech intelligibility.
-
公开(公告)号:US20240342509A1
公开(公告)日:2024-10-17
申请号:US18631128
申请日:2024-04-10
IPC分类号: A61N7/00
CPC分类号: A61N7/00 , A61N2007/0034 , A61N2007/0078
摘要: A device for stationary delivery of focused ultrasound therapy to a body surface treatment area of a patient includes a plurality of ultrasound emitters arranged in a flexible array, each emitter of the plurality of emitters having a polygonic geometry and a plurality of edges. At least one edge of each emitter is adjacent to and forms a narrow gap between the at least one edge and an edge of at least one other emitter of the plurality of emitters. Each emitter has an external face and an opposite internal face. The flexible array provides an area of uniform emitter coverage so that uniform ultrasonic waves are applied to the body surface treatment area of the patient when the device is placed onto, so as to conform to, a curvature of the body surface treatment area, and the external face of each emitter is adjacent to the treatment area.
-
47.
公开(公告)号:US20240342501A1
公开(公告)日:2024-10-17
申请号:US18640122
申请日:2024-04-19
发明人: Norton HERRICK , Miles HERRICK , Sean HAGBERG , David MUEHSAM , David SALOFF
CPC分类号: A61N2/02 , A61H23/0218 , A61N2/004 , A61N5/0613
摘要: Methods and devices for reducing inflammation by reducing pro-inflammatory cytokines molecules and increasing anti-inflammatory signaling molecules in a mammal are provided. A device can include a power supply; an amplifier; an antenna, and a waveform generator. The one or more signals can have an aperiodic continuous waveform function or an aperiodic pulse train that reduces inflammation, reduce pro-inflammatory cytokines molecules, and/or increases anti-inflammatory signaling molecules in a mammal.
-
公开(公告)号:US20240342500A1
公开(公告)日:2024-10-17
申请号:US18383005
申请日:2023-10-23
发明人: John T. Butters , Bennett M. Butters , Mike Ammerman , Scott Conway , Robert Fish , Larry Hood , Jared Nathanson , Kevin Oberkramer , Kathryn Kukulka , Andrew March
CPC分类号: A61N2/02 , A61N2/002 , A61N2/004 , G01N37/005 , A61B2562/0223 , A61M2037/0007 , A61M2250/00
摘要: Disclosed herein are systems and methods for providing a portable magnetic field therapy system for inducing an effect of a chemical or biochemical agent to a mammalian subject, such as for the treatment of diseases and adverse health conditions.
-
公开(公告)号:US20240342495A1
公开(公告)日:2024-10-17
申请号:US18579604
申请日:2022-07-13
发明人: Anthony Robert PRISCO , Alex DEAKYNE , Marinos KOSMOPOULOS , David BENDITT , Pierre SEBASTIAN , Demetris YANNOPOULOS
IPC分类号: A61N1/39
CPC分类号: A61N1/39044 , A61N1/3993
摘要: Embodiments comprise an electrocardiograph device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a classifier, and a display device. The classifier comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor the processor to receive the ECG data, and generate a determination indicating whether the ventricular fibrillation event has been caused by heart muscle ischemia based on the model, the parameters of the model. The display device is configured to output the determination, which can also be communicated to follow-on provider systems. The determination can also indicate a predicted coronary perfusion pressure.
-
公开(公告)号:US20240342487A1
公开(公告)日:2024-10-17
申请号:US18682569
申请日:2022-08-24
申请人: BaroPace, Inc.
发明人: Michael BURNAM
CPC分类号: A61N1/3629 , A61N1/025 , A61N1/36564 , G16H10/60 , G16H40/67
摘要: Techniques and systems disclosed herein are directed to determining pacing attributes for a patient and include determining use of a beta blocker with intrinsic sympathomimetic activity (ISA) by the patient, receiving a current physiological input, and determining pacing attributes based on the determining use of the beta blocker with ISA and the current physiological input. They further include receiving a current physiological input, determining pacing attributes based on the current physiological input, causing a pacing device to output pacing outputs based on the pacing attributes, receiving an updated physiological input after causing the pacing device to output the pacing outputs, determining that a difference between the current physiological input and the updated physiological input does not meet a threshold difference, and generating an indication of a presence or use of a non-ISA beta blocker based on the difference not meeting the threshold difference.
-
-
-
-
-
-
-
-
-